1. Scrip
  2. >>Business
  3. >>Deals

Horizon Megadeal: J&J Out, Experts Say Sanofi Could Have Edge On Amgen

 
• By Ayisha Sharma

Janssen has dropped out of the running to acquire Irish biotech Horizon, leaving Sanofi and Amgen to vie over the potential megadeal, with some observers identifying the former as the better fit.    

Two people running in race against sunset horizon background
Sanofi And Amgen Remain In The Race For Horizon • Source: Shutterstock

Janssen Pharmaceuticals Inc. has revealed it has no intention to place a bid on Horizon Therapeutics plc less than a week after the Dublin-based biotech was forced to reveal under Irish Takeover Rules that it was engaging in early discussions with three big pharma firms.

J&J dropping out of the race leaves Amgen, Inc. and Sanofi as the two remaining contenders. Both companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 
• By Dexter Jie Yan

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 
• By Joseph Haas, Manas Mishra, and Sushmita Panda

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.